The Diagnostic Performance of 24-hour Urinary Aldosterone for Primary Aldosteronism
NCT ID: NCT06236698
Last Updated: 2025-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
999 participants
OBSERVATIONAL
2022-03-01
2024-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Previous studies reported that primary aldosteronism is associated with a higher risk of CV complications and a higher prevalence of target organ damage. Also, previous studies reported on the association of echocardiographic parameters with circulating or urinary aldosterone. Therefore, we intent to investigate the independent associations of different target organ damage with the urinary excretion of aldosterone.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Plasma Metabolomics Profiling of Primary Aldosteronism
NCT06500000
Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism
NCT03500120
Simplification of Oral Sodium Loading Test in the Diagnosis of Primary Aldosteronism: 2-day Replacing 3-day Method
NCT06750172
Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone
NCT06047912
Diagnosing Variable Primary Aldosteronism.
NCT05765786
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Essential hypertension
Adult patients meet the 2018 Chinese guidelines for prevention and treatment of hypertension for a diagnosis of essential hypertension but without other obvious features of PA.
24-hour urinary aldosterone measurement
Collect 24-hour urine sample from each participant and complete the detection of urinary aldosterone content.
Primary aldosteronism
Adult patients meet the Endocrine Society Clinical Practice Guidelines for a diagnosis of primary aldosteronism.
24-hour urinary aldosterone measurement
Collect 24-hour urine sample from each participant and complete the detection of urinary aldosterone content.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
24-hour urinary aldosterone measurement
Collect 24-hour urine sample from each participant and complete the detection of urinary aldosterone content.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Meets the 2018 Chinese guidelines for prevention and treatment of hypertension for a diagnosis of hypertension with an age of onset of hypertension between 18-80 years.
3. Meets the Endocrine Society Clinical Practice Guidelines for a diagnosis of primary aldosteronism with an age of onset of hypertension between 18-80 years.
Exclusion Criteria
2. Urine output less than 400ml per day.
3. Severe renal insufficiency with a glomerular filtration rate \< 60 mL/min/1.73 m2.
4. lack of 24-h urinary aldosterone data.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhiming Zhu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhiming Zhu
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhiming Zhu, MD
Role: STUDY_CHAIR
Department of Hypertension and Endocrinology, Daping Hospital, Army Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China Chongqing The third hospital affiliated to the Third Millitary Medical University
Chongqing, Chongqing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
The value of 24h UA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.